Equities researchers at Piper Jaffray Companies began coverage on shares of Fate Therapeutics (NASDAQ:FATE) in a research report issued on Monday, MarketBeat reports. The brokerage set an “overweight” rating and a $10.00 price target on the biopharmaceutical company’s stock. Piper Jaffray Companies’ target price would indicate a potential upside of 129.36% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 6th. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Fate Therapeutics in a research report on Friday, November 10th. ValuEngine lowered shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. BMO Capital Markets reaffirmed a “buy” rating and set a $7.00 price target on shares of Fate Therapeutics in a research note on Thursday, November 2nd. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Fate Therapeutics in a research note on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. Fate Therapeutics has an average rating of “Buy” and a consensus price target of $7.25.

Shares of Fate Therapeutics (NASDAQ FATE) traded up $0.17 during midday trading on Monday, hitting $4.36. 411,955 shares of the company’s stock traded hands, compared to its average volume of 299,772. Fate Therapeutics has a 52 week low of $2.40 and a 52 week high of $5.68. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.21 and a current ratio of 7.21.

Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The company had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.95 million. Fate Therapeutics had a negative return on equity of 64.55% and a negative net margin of 935.09%. The business’s quarterly revenue was up .0% on a year-over-year basis. analysts forecast that Fate Therapeutics will post -0.99 EPS for the current year.

In other news, General Counsel Cindy Tahl sold 8,091 shares of Fate Therapeutics stock in a transaction on Monday, October 16th. The stock was sold at an average price of $3.85, for a total transaction of $31,150.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Daniel D. Shoemaker sold 13,225 shares of Fate Therapeutics stock in a transaction on Monday, October 16th. The stock was sold at an average price of $3.87, for a total value of $51,180.75. The disclosure for this sale can be found here. Insiders own 10.88% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. New York State Common Retirement Fund acquired a new position in shares of Fate Therapeutics during the 2nd quarter worth $131,000. Rhumbline Advisers acquired a new position in Fate Therapeutics in the 2nd quarter valued at about $133,000. Hochman Cole Investment Advisors Inc. acquired a new position in Fate Therapeutics in the 3rd quarter valued at about $158,000. Schwab Charles Investment Management Inc. acquired a new position in Fate Therapeutics in the 2nd quarter valued at about $214,000. Finally, California State Teachers Retirement System acquired a new position in Fate Therapeutics in the 2nd quarter valued at about $219,000. 60.97% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/12/18/piper-jaffray-companies-begins-coverage-on-fate-therapeutics-fate.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.